The aim of this study was to identify trends in high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (ASCT) and to assess survival in a large cohort of breast cancer (BC) patients receiving this therapy in Europe from 1990 to 1999. A total of 7471 patients who received HDC with ASCT between January 1, 1990 and December 31, 1999 were reported to the European Group for Blood and Marrow Transplantation Registry. Data required for demographics and survival analysis were available for 2679 patients with high-risk primary BC; 921 patients with inflammatory BC (IBC), and 2295 patients with metastatic disease. The main evaluation parameters were progression-free survival (PFS) and overall survival (OS). Between 1990 and 1998, autotransplants for BC increased 30-fold. Significant trends included use of blood-derived rather than marrow-derived stem cells, increment of reporting centers and decrease of mortality within 100 days from transplantation. The 5-year PFS and OS probabilities were 53 and 68% for high-risk disease and 42 and 53% for IBC, respectively. For metastatic disease 5-year PFS and OS probabilities in the whole cohort were 18 and 27%, respectively, while for women transplanted in complete remission the 5-year PFS was 29%. In conclusion, HDC with ASCT has been increasingly used until 1998 and the 100-day mortality rate has been constantly less than 2% from 1995 to date. The 5-year survival of high-risk BC is related to the number of axillary nodes involved at surgery. Outcome of patients with IBC is encouraging, suggesting the need for randomized trials. Patients with metastatic disease responding to pretransplant chemotherapy and harboring ER+ tumors have a better outcome. Despite improvements in early detection and adjuvant therapies, breast cancer (BC) remains a leading cause of cancer death in Western countries. Mortality at 10 years exceeds 60% for those patients with 10 or more involved nodes at surgery or large primary tumors, and nearly all women diagnosed with metastatic BC ultimately die of their disease. 1, 2 Nowhere has there been more controversy in recent years than in the use of high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (ASCT) for BC. Early trials of HDC, based on favorable laboratory and clinical indicators, 3, 4 initiated in the early 1980s, suggested that this approach might favorably affect the course of operable, high-risk primary and metastatic BC (MBC). 5 Phase II studies created positive expectations among physicians and their patients, to such an extent that HDC with ASCT also became widely used as a therapeutic option outside controlled trials. The use of peripheral blood (PB) cells instead of bone marrow (BM) for ASCT 6, 7 significantly reduced the morbidity and mortality related to HDC 8, 9 and allowed the utilization of this procedure also outside specialized or academic centers. 10 However, after almost two decades of clinical research in this field and thousands of women with BC receiving HDC, the appropriate role of this approach remains today uncertain. Most of the randomized trials reported in the last few years, [11] [12] [13] [14] [15] although demonstrating the noninferiority of HDC, have failed to show a survival benefit, although the follow-up was generally short and the number of patients was in some cases too small to reach the expected survival benefit. 16 In addition, because of the heterogeneity of intensity and duration of the standard dose chemotherapy (SDC) in the control arm, the outcomes of these studies have been quite variable. 17 As a contribution to the ongoing discussion on HDC for BC we report here the results of this therapeutic approach in almost 6000 women receiving ASCT at 370 European Group for Blood and Marrow Transplantation (EBMT) centers between 1990 and 1999.
Bone Marrow Transplantation

Methods
Patients
The EBMT Solid Tumors Registry was set up in 1984 to collect information regarding patients undergoing HDC and ASCT in Europe and the Middle East. EBMT centers are required to send patient data each year to the Central EBMT Database either directly, or through a National Registry where it exists. There are two levels of data: Minimal Essential Data type A (MED A) which are compulsory and consider major items such as demographic data, disease classification, type of transplant outcomes and follow-up; and Minimal Essential Data B (MED B) referring to items sent on a volunteer basis (type of conditioning or mobilization regimens, complications, number of cells transplanted, etc). A total of 10 centers each year are randomly requested to be audited by an EBMT committee in order to verify the quality of the reported data and to compare them with the ones of a general European survey performed yearly on behalf of the EBMT where only number of patients and type of graft and disease are requested. 19, 20 Before starting the present evaluation regarding the decade 1990-1999, all centres were recontacted for missing data. Among 7471 BC patients reported to the EBMT Registry, 5895 were eligible for this retrospective analysis and represent the body of this paper. A total 2679 were reported as having high-risk BC, 921 inflammatory BC (IBC) and 2295 metastatic disease. Cases with an incomplete data set have been excluded from the analysis.
Statistical analysis
Probabilities of 100-day mortality, progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier product limit estimate. 21 The log-rank test was used for comparisons of PFS and survival between groups. 22 OS and PFS rates were measured from the date of transplant to the date of last follow-up or death and the date of progression, respectively.
Results
Between January 1, 1990 and December 31, 1999, 7471 patients with BC receiving HDC and HSCT were reported to the EBMT Registry, which represents 49% of all cases of solid tumors in the database. Demographics and essential clinical data are reported in Table 1 .
During the decade, the number of ASCT, along with the number of reporting centers for BC, increased progressively until 1998 (Table 1) for all disease stages. During the following years, a rapid decline in the number of ASCT for BC has been observed, that is, 1115 (À32%) in 1999 and 762 (À32%) in 2000 (EBMT Solid Tumor Working Party, annual reports). Between 1992 and 1994, a dramatic shift toward a widespread use of PB progenitors occurred (19 and 91%, respectively). Transplant-related mortality, that is, any death not related to the disease occurring within the first 100 days after the graft, declined in the second half of the decade, to 1-2%.
Owing to the elevated number of phase II studies, the conditioning regimens employed are quite different (Tables 2 and 3 ). The cyclophosphamide/thiotepa/carboplatin (STAMP V) or its variants was the most frequently used schedule in the adjuvant setting, while high-dose sequential chemotherapy 15 or its variants, largely used in Italy, ranked second. STAMP V was the most frequently used regimen also in MBC while mitoxantrone/cyclophosphamide/melphalan, which is utilized mainly in France, ranked first in IBC. Overall, 25 different regimens in stage 
High-risk primary breast cancer
Relevant patient characteristics are reported in Table 2 . Among 1165 patients with fully available data, 35% had o10 positive axillary nodes, and 54% had X10 positive nodes. A proportion of cases had been treated for very high-risk BC, that is, X20 positive nodes (n ¼ 130; 11%). Kaplan-Meier estimates of OS and PFS of the whole cohort of adjuvant patients and subgroups with different lymph node involvement are reported in Figure 1 . Median PFS for the whole high-risk group and those with X10 positive nodes were 74 and 69 months (Figure 1 a and b) , respectively; for patients receiving HDC with less than 10 positive nodes, median PFS was not reached (Figure 1b ). In patients with X20 positive nodes at surgery, survival rates significantly dropped (median DFS ¼ 37 months)
(Figure 1c). No statistically significant difference was observed in OS and PFS regarding estrogen-receptor (ER) status (data not shown).
Inflammatory breast cancer
The EBMT BC Registry includes 921 patients with nonmetastatic IBC treated with HDC, which corresponds to a rather elevated percentage of 25% of all stage II/III patients when compared to the ABMTR survey. Although there is no definitive explanation for these data, the tendency toward ASCT for this disease has been rather high in Europe. In fact, several studies in France have specifically investigated the role of HDC in IBC. Patient characteristics and survival rates are shown in Table 2 and Figure 1d . Median time to progression after transplant was 40 months.
Metastatic breast carcinoma
Characteristics of women who received HSC with ASCT for MBC are listed in Table 3 . A total of 28% of all patients were given HDC as consolidation after achieving a complete response (CR) with conventional treatments. Overall and PFS of the whole cohort of patients are reported in Figure 2a ; median OS and PFS were 31 and 13 months, respectively. Patients receiving HDC with ASCT in first CR had a significantly better PFS compared to those receiving this therapy in partial response, stable disease or progression (median 25 vs 13 months, Fig. 2b ). Poorer outcomes were associated with ERnegative tumors (31 vs 43% OS at 5 years ) ( Figure 2c ) and a shorter interval between diagnosis and transplant (data not shown). 
Discussion
As a result of high expectations for the role of HDC as a treatment for BC, the number of transplants performed in Europe consistently increased from 1990 to 1998. In more recent years, the number of procedures has diminished due to premature reports from randomized trials that did not show the expected survival advantage in favor of HDC. Highs and lows in the enthusiasm for HDC in BC has been largely unreasonable since no definitive conclusions can be drawn despite a huge number of studies reported throughout the last two decades. 16, 17 This has cast a pall over the entire field and has resulted in both a low accrual of early prospective trials (irrational exuberance phase) and a moratorium on new studies (reticence phase).
The EBMT Registry data confirm that HDC with ASCT today is a safe procedure. Mortality rate within 100 days from transplantation has significantly reduced during the last decade, possibly related to the use of blood cells as source of HSC and a widespread better knowledge of the whole procedure. Moreover, the overall low mortality rate might also be related to the use of preparative regimens with a low toxicity profile, that is, the cyclophosphamide/ BCNU/ cisplatin (STAMP I) regimen, which is associated with a high treatment-related mortality, 14 is only anecdotally reported in European surveys. 10 It is worth noting that the switch from BM to PB as the source of stem cells occurred rapidly in mid-1990s and the reinfusion of BM plus PB stem cells has been utilized in a minority of patients in Europe (ie 12% in 1993, 0.25% in 1995) compared to the higher rate reported in the North American Registry. 23 This might be related to legal issues, which were more stringent in the US, or possibly to a earlier confidence of European physicians on the durability of hematopoiesis following autografting of PB cells. 24 The clinical results of our retrospective analysis should be viewed considering that patients receiving HDC differ from the general population of women with BC. Thus, differences observed between patients receiving transplantation and those who received SDC in historical data bases may result from selection biases. This underscores the importance of comparing HDC and SDC in comparable subjects within large randomized trials. Unfortunately, the outcomes of the phase III studies so far reported had been quite variable, this partially depending on their heterogeneity and the lack of sufficient numbers of patients to assess interventions with adequate statistical power. 15 In addition, they have been reported in some cases without ASCT for breast cancer in Europe P Pedrazzoli et al sufficient follow-up. 11, 25 Our retrospective analysis, including almost 6000 patients reported in the EBMT Registry, may be useful in complementing data from these randomized trials. It allows the following clinical considerations.
In the 934 evaluable patients with high-risk primary BC, defined by extensive axillary node involvement, our data confirm that survival is related to the number of positive nodes at surgery, but not to the ER status. Results presented here cannot be compared with previous reports of SDC and the controversy about the efficacy of HDC for high-risk BC remains unsettled. The available results of six large phase 3 studies, [13] [14] [15] [26] [27] [28] only one having been published in a peer-reviewed journal, 13 are still too preliminary, while in two studies the control arms were not conventional therapies. 13, 14 In the 921 patients with IBC, our data suggest an apparent advantage in DFS rates from the inclusion of HDC in the multidisciplinary management of this disease. [29] [30] [31] Randomized trials in this subgroup of patients are necessary to evaluate the potential benefits of such a strategy.
In the large cohort of 2230 patients with MBC, women receiving HDC as consolidation therapy after achieving CR had the best prognosis, with one out of four patients being disease-free at 5 years. This result confirms the data from the ABMTR 18, 23, 32 and suggests that HDC with ASCT may cure a subset of patients with MBC. 33 Despite these encouraging results, available data from randomized trials reported to date are contradictory. It is noteworthy that three trials, 11, 12, 34 which addressed the value of consolidation with HDC vs SDC in chemosensitive patients, were undersized as to the number of patients transplanted in CR. This aspect seems critical in interpreting their results, as patients in CR are those who are likely to benefit most from HDC. In our analysis time to relapse and ER-positive disease were associated with a better outcome as previously reported. 32 Based on the results of this analysis, we recommend that continued investigation of high-dose strategies is still necessary. The information presented here, as well as the maturing of data from large controlled studies should guide future trials aimed at identifying subsets of patients who are more likely to benefit from HDC. Further improvement of HDC with ASCT is likely to come, in the near future, by integrating HDC with novel treatment strategies with different and potentially complementary mechanisms of action.
